In order for cell therapies to scale effectively, the industry is clamouring for standardisation around things like manufacturing and treatment administration.
Innovative, advanced therapies have enormous promise, but also come with a host of logistical problems that innovators underestimate at their own peril.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh